Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
[4] [6] All dosing information in the public domain derives exclusively from clinical trial protocols, which are conducted under strict ethical oversight and continuous medical supervision
Coverage may be considered only if the medication receives FDA approval in the future
The company specializes in synthetic peptides, offering Retatrutide lyophilized powder in standard dosages (5 mg, 10 mg, 20 mg) and supporting custom dosages, logo packaging, and full ODM services
GLP-1 Receptor Agonist Market Highlights: North America registered dominance of the global market share by 76% in 2024
In a 2010 clinical trial, for example, subjects who received tesamorelin ended with an average 18% decrease in visceral fat compared to placebo.27 This fat-reducing quality is what makes tesamorelin an attractive non-GLP-1 peptide option
Glucagon Receptor: This third pathway is unique to Retatrutide and directly increases energy expenditure
